(Source: Actelion Ltd) Uptravi approved for treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression and reduce the risk of hospitalization for PAH Uptravi will be made available to patients in the US in early January 2016 Uptravi will become a significant treatment option in PAH and complements Actelion's portfolio with Opsumit and Veletri ALLSCHWIL, SWITZERLAND - 22 December 2015 - Actelion (SIX: ATLN) announced today that the United States Food and Drug Administration (FDA) has approved the use of the orally active, selective IP prostacyclin receptor agonist Uptravi (selexipag),originally discovered and synthesized by Nippon Shinyaku, for the treatment...
↧